Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

May 24, 2021

May 24, 2021 02:58 PM Eastern Daylight Time

BROOKLYN, N.Y.–(BUSINESS WIRE)–Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced it has completed a $20M financing to progress the development of the mRNA gene editing and cell therapies technology recently licensed from Factor Biosciences and Novellus Therapeutics. The Company intends to utilize the funds to commence translation of the gene-editing, cellular therapy, and nanolipid particle platform into its emerging clinical programs with a focus on orphan diseases, such as sickle cell anemia, familial amyloidosis, and cell therapies for cancer.